This review evaluated the association between breast cancer subtypes and the risk of recurrence (return of the cancer) in breast cancer patients. 

This study investigated what antiplatelet drugs are most effective and safe for preventing stroke in patients with cardiovascular disease or who have a history of stroke. 

The authors evaluated the impact of prostate cancer on the quality of life of prostate cancer survivors.  

This study investigated whether a high proportion of dense breast tissue is associated with an increased risk of developing contralateral breast cancer (CBC, cancer in the other breast). This study determined that those with dense breasts at the time of original diagnosis were significantly more likely to develop CBC than those without.

This article reviewed the guidelines for the continued care of prostate cancer survivors following successful treatment. 

This paper studied the effectiveness of the antiplatelet therapy drugs clopidogrel (Plavix) and aspirin on stroke prevention.

This review evaluated the effects of physical activity on the survival of breast cancer patients.

This study evaluated the use of alendronate (Fosamax) for the prevention of bone loss in men undergoing androgen deprivation therapy (ADT) for localized prostate cancer.

This study examined the efficiency of statins in preventing strokes among high-risk patients.

Could cannabis also be a cure?

This review explored the use of cannabinoids in the treatment of breast cancer.

Medical cannabis, as well as multiple cannabinoid-based drugs, have long been used to treat cancer symptoms, such as cancer-related pain and the nausea and vomiting associated with chemotherapy. Cannabinoids are known to be safe and well-tolerated among cancer patients, and patients receiving medical cannabis often report significant improvements in quality of life.

Recently, research has begun to explore the use of cannabinoids as a possible treatment for breast cancer rather than simply a symptomatic therapy. The current review analyzed recent research investigating cannabinoids as a possible therapy for different types of breast cancer.

This review focused on pre-clinical research, investigating tumor cells taken from breast cancer patients or animal models. No clinical trials involving human breast cancer patients were reviewed.
Overall, cannabinoids have been shown to block cancer cell proliferation and reduce cancer cell migration in all breast cancer subtypes.

THC (tetrahydrocannabinol), the most commonly investigated cannabinoid, has been found to reduce both the rate of tumor growth and the overall number of developing tumors in HER2-positive breast cancer through the reduction of cell proliferation and by increasing cancer-cell death.  Some studies have also shown cannabinoids to decrease the formation of blood vessels within the tumor, which inhibits cancer growth.

The cannabinoid receptor type 2 (CB2) receptor (a complex found on the surface of cells) has been identified as the receptor responsible for many of the beneficial effects of cannabinoids. High amounts of CB2-receptors have been found to be more commonly associated with HER2-positive or triple-negative breast cancer cells. In models investigating triple-negative breast cancer, stimulation of the CB2-receptor with a cannabinoid-based drug,  JWH-133, lead to a significant decrease in the number of proliferating cancer cells, as well as blood vessel growth within the tumor.